Inhibitor Therapeutics Income Statement (2012-2026)

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Shares Outstanding (Entity) (Quarter)	375.88M	376.86M	376.86M	376.86M	376.86M	376.86M	366.18M	171.79M	171.97M	172.02M	172.02M	172.32M	172.32M	172.32M	172.32M	172.32M	172.57M	172.57M	172.57M	172.57M
Operating items
Research & Development (Quarter)	950.00		75.00		0.01M			0.20M	0.23M	0.26M	0.68M	0.26M	0.24M	0.37M	0.89M	0.24M	0.33M	0.38M	0.76M	0.34M
Selling, General & Administrative (Quarter)	0.06M	0.07M	0.03M	0.09M	0.06M	0.07M	0.42M	0.43M	0.51M	0.50M	0.59M	0.51M	0.35M	0.44M	0.60M	0.44M	0.37M	0.36M	0.56M	0.36M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)	0.06M	0.07M	0.03M	0.09M	0.07M	0.07M	0.42M	0.63M	0.74M	0.76M	1.27M	0.77M	0.59M	0.81M	1.48M	0.67M	0.70M	0.74M	1.32M	0.70M
Operating Income (Quarter)	-0.06M	-0.07M	-0.03M	-0.09M	-0.07M	-0.07M	-0.42M	-0.63M	-0.74M	-0.76M	-1.27M	-0.77M	-0.59M	-0.81M	-1.48M	-0.67M	-0.70M	-0.74M	-1.32M	-0.70M
EBIT (Quarter)	-0.06M	-0.07M	-0.03M	-0.09M	-0.07M	-0.07M	-0.42M	-0.63M	-0.74M	-0.76M	-1.27M	-0.77M	-0.59M	-0.81M	-1.48M	-0.67M	-0.70M	-0.74M	-1.32M	-0.70M
Non-operating items
Interest & Investment Income (Quarter)								0.09M	0.09M	0.09M	0.11M	0.09M	0.08M	0.08M	0.06M	0.04M	0.04M	0.03M	0.02M	0.01M
Other Non Operating Income (Quarter)
Net income details
EBT (Quarter)	-0.07M	-0.07M	-0.03M	-0.10M	-0.08M	-0.08M	-0.43M	-0.57M	-0.65M	-0.67M	-1.26M	-0.73M	-0.57M	-0.83M	-1.46M	-0.64M	-0.69M	-0.72M	-1.31M	-0.89M
Profit After Tax (Quarter)	-0.07M	-0.12M	-0.03M	-0.10M	-0.08M	-0.08M	12.36M	-0.54M	-0.65M	-0.66M	-1.17M	-0.68M	-0.50M	-0.73M	-1.42M	-0.63M	-0.66M	-0.71M	-1.30M	-0.70M
Income from Non-Controlling Interests (Quarter)
Income from Continuing Operations (Quarter)	-0.07M	-0.07M	-0.03M	-0.10M	-0.08M	-0.08M	-0.43M	-0.57M	-0.65M	-0.67M	-1.26M	-0.73M	-0.57M	-0.83M	-1.46M	-0.64M	-0.69M	-0.72M	-1.31M	-0.89M
Consolidated Net Income (Quarter)	-0.07M	-0.07M	-0.03M	-0.10M	-0.08M	-0.08M	-0.43M	-0.57M	-0.65M	-0.67M	-1.26M	-0.73M	-0.57M	-0.83M	-1.46M	-0.64M	-0.69M	-0.72M	-1.31M	-0.89M
Income towards Parent Company (Quarter)	-0.12M	-0.12M	-0.08M	-0.15M	-0.13M	-0.13M	-0.43M	-0.57M	-0.65M	-0.67M	-1.26M	-0.73M	-0.57M	-0.83M	-1.46M	-0.64M	-0.69M	-0.72M	-1.31M	-0.89M
Preferred Dividend Payments (Quarter)	0.05M	0.05M	0.05M	0.05M	0.05M	0.05M	0.04M
Net Income towards Common Stockholders (Quarter)	-0.12M	-0.12M	-0.08M	-0.15M	-0.13M	-0.13M	12.32M	-0.54M	-0.65M	-0.66M	-1.17M	-0.73M	-0.57M	-0.83M	-1.46M	-0.64M	-0.69M	-0.72M	-1.31M	-0.89M
Additional items
EPS (Basic) (Quarter)	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	-0.01	-0.01
EPS (Diluted) (Quarter)	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	-0.01	-0.01
Shares Outstanding (Quarter)	375.88M	376.71M	376.25M	376.86M	376.86M	376.86M	366.18M	171.79M	171.97M	172.01M	171.95M	172.08M	172.32M	172.32M	172.26M	172.32M	172.57M	172.57M	172.51M	172.57M
Shares Outstanding (Diluted) (Quarter)	375.88M	376.71M	376.25M	376.25M	376.86M	376.86M	367.78M	171.79M	171.97M	172.01M	171.95M	172.08M	172.32M	172.32M	172.26M	172.32M	172.57M	172.57M	172.51M	172.57M
EBITDA (Quarter)	-0.06M	-0.07M	-0.03M	-0.09M	-0.07M	-0.07M	-0.42M	-0.63M	-0.74M	-0.76M	-1.27M	-0.77M	-0.59M	-0.81M	-1.48M	-0.67M	-0.70M	-0.74M	-1.32M	-0.70M
Interest Expenses (Quarter)	0.00M	0.00M	0.00M	0.01M	0.01M	0.01M	0.00M	0.03M		0.01M	0.09M	0.05M	0.07M	0.10M	0.03M	0.01M	0.03M	0.01M	0.01M	0.20M

Research Tools

Datasets

Plans

Developers

Inhibitor Therapeutics INTI Income Statement (2012-2026)

Research Tools

Datasets

Plans

Developers

Inhibitor Therapeutics INTI Income Statement (2012-2026)

Create an account

Sign In

Reset Password